2. Metabolic Enzyme/Protease Apoptosis Immunology/Inflammation
  3. Fatty Acid Synthase (FASN) Apoptosis Interleukin Related Toll-like Receptor (TLR) NOD-like Receptor (NLR) Caspase
  4. Xelafaslatide

Xelafaslatide (ONL-1204) is a Fas receptor antagonist. Xelafaslatide blocks the Fas receptor signaling pathway and inhibits downstream apoptosis and inflammatory pathways. Xelafaslatide suppresses neuroinflammation and microglial activation in glaucoma models, protects retinal ganglion cells and prevents axonal degeneration. Xelafaslatide is applicable to relevant research on glaucoma.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Xelafaslatide

Xelafaslatide Chemical Structure

CAS No. : 2040964-58-5

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Xelafaslatide Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms
NLRP3 NLRP1 NOD1 NOD2

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Xelafaslatide (ONL-1204) is a Fas receptor antagonist. Xelafaslatide blocks the Fas receptor signaling pathway and inhibits downstream apoptosis and inflammatory pathways. Xelafaslatide suppresses neuroinflammation and microglial activation in glaucoma models, protects retinal ganglion cells and prevents axonal degeneration. Xelafaslatide is applicable to relevant research on glaucoma[1].

IC50 & Target[1]

IL-6

 

IL-1β

 

Caspase 8

 

TLR4

 

NLRP3

 

In Vitro

Xelafaslatide (15-125 μM; 4 h-overnight) dose-dependently blocks FasL-mediated apoptosis of murine A20 B lymphoma cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Xelafaslatide Related Antibodies

Apoptosis Analysis[1]

Cell Line: murine A20 B lymphoma cells
Concentration: 15 μM, 30 μM, 60 μM, 125 μM
Incubation Time: 4 h (with mFasL-VP); overnight (with 3H-thymidine)
Result: Inhibited mFasL-induced apoptosis of A20 cells in a dose-dependent manner.
Significantly increased cell survival at all tested concentrations relative to vehicle-treated mFasL-VP-exposed cells.
In Vivo

Xelafaslatide (2 μg/1 μL; intravitreal administration; single dose) achieves complete neuroprotection of retinal ganglion cells and optic nerve axons, inhibits retinal microglial activation, and blocks the induction of glaucoma-related inflammatory genes in a microbead-induced mouse glaucoma model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J wild-type (8-week-old, glaucoma model induced by anterior chamber injection of 15-μm polystyrene microbeads)[1]
Dosage: 2 μg per 1 μL
Administration: intravitreal; single dose (day 0, prior to microbead injection)
Result: Achieved RGC density equivalent to saline-injected control mice, fully preventing microbead-induced RGC loss.
Attained optic nerve axon density equivalent to saline-injected control mice, fully preventing microbead-induced axon loss.
Preserved a quiescent, dendritic morphology in Iba1+ retinal microglia (ganglion cell layer/inner plexiform layer), with significantly longer microglial cell processes compared to vehicle-treated microbead-injected mice.
Abrogated the microbead-induced upregulation of multiple inflammatory and glial activation genes (including GFAP, Caspase-8, TNFα, IL-1β, IL-18, IL-6, MIP-1α, MIP-1β, MIP-2, MCP1, IP10, C3, C1Q, TLR4, and NLRP3), with gene expression levels equivalent to saline-injected controls.
Molecular Weight

1461.66

Formula

C71H100N18O16
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2
Sequence Shortening

HHIYLGAVNYIY-NH2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (68.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.6842 mL 3.4208 mL 6.8415 mL
5 mM 0.1368 mL 0.6842 mL 1.3683 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (1.71 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.88%

SDS (252 KB)

COA (246 KB) RP-HPLC (247 KB) MS (73 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.6842 mL 3.4208 mL 6.8415 mL 17.1038 mL
5 mM 0.1368 mL 0.6842 mL 1.3683 mL 3.4208 mL
10 mM 0.0684 mL 0.3421 mL 0.6842 mL 1.7104 mL
15 mM 0.0456 mL 0.2281 mL 0.4561 mL 1.1403 mL
20 mM 0.0342 mL 0.1710 mL 0.3421 mL 0.8552 mL
25 mM 0.0274 mL 0.1368 mL 0.2737 mL 0.6842 mL
30 mM 0.0228 mL 0.1140 mL 0.2281 mL 0.5701 mL
40 mM 0.0171 mL 0.0855 mL 0.1710 mL 0.4276 mL
50 mM 0.0137 mL 0.0684 mL 0.1368 mL 0.3421 mL
60 mM 0.0114 mL 0.0570 mL 0.1140 mL 0.2851 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Xelafaslatide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Xelafaslatide2040964-58-5ONL-1204ONL1204ONL 1204Fatty Acid Synthase (FASN)ApoptosisInterleukin RelatedToll-like Receptor (TLR)NOD-like Receptor (NLR)CaspaseILretinal ganglion cellchemokinespro-inflammatory genesaxon degenerationinflammasome pathway mediatorsretinal microgliacomplement cascade componentsToll-like receptor pathway mediatorscytokinesFas receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Xelafaslatide
Cat. No.:
HY-P10227
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.